Compare iShares MBS ETF (MBB) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MBS ETF vs Neurocrine Biosciences Inc — how do they compare? iShares MBS ETF trades at $93.28, while Neurocrine Biosciences Inc trades at $157.33 (market cap $16.46B). The key difference: Neurocrine Biosciences Inc is trading nearer its 52-week high, iShares MBS ETF nearer its low. Which is the better fit depends on your goals.
| MBB | NBIX | |
|---|---|---|
52-Week High | $96.91 | $185.50 |
52-Week Low | $92.72 | $123.10 |
Market Cap | — | $16.46B |
Sector | — | Health |
Enterprise Value | — | $16.48B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MBB trades at $93.28, up 0.38% on the day, with a bearish technical signal from moving averages and neutral oscillators. Recent corporate actions include dividend payments of $0.33-$0.34 per share in mid-2026. Focus Financial Network increased its stake by 13.8% in the latest quarter, holding 49,056 shares as of its most recent SEC filing.
The outlook remains cautious due to bearish technical indicators and limited fundamental data availability. Key risks include market volatility and reliance on institutional interest. Investment opportunities hinge on dividend income and potential institutional accumulation, but the lack of current financial metrics warrants careful evaluation.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MBS ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index and TBAs that have economic characteristics that are substantially identical to the economic characteristics of the component securities of the index, and the fund will invest at least 90% of its assets in fixed income securities included in the underlying index that advisor believes will help the fund track the index.
Read more on MBB →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
